View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Barco NV: 2 directors

Two Directors at Barco NV bought 136,190 shares at 13.000EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Castellum AB: 2 directors

A director at Castellum AB bought 3,633 shares at 126.950SEK and the significance rating of the trade was 42/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Thomson Reuters Corp: 4 directors

Four Directors at Thomson Reuters Corp sold 7,686 shares at between 164.400USD and 168.120USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

Nick Scali: 1 director

A director at Nick Scali bought 25,000 shares at 14.693AUD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Scandi Standard AB: 3 directors

A director at Scandi Standard AB bought 100,000 shares at 72.250SEK and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Klaus Breitenbach
  • Klaus Breitenbach

Berentzen–Gruppe Aktiengesellschaft : Q1 2024 – Earnings and profitabi...

>Group revenue in line, EBIT margins above estimate - Berentzen reported Q1 2024 revenue of € 40.9m (in line with ODDO BHF) but slightly down y-o-y. The reason for the decline was that 1) the cooperation business with prominent artists in the Non-alcoholic Beverages segment was terminated last year and 2) several high-revenue marketing campaigns were not conducted in the first three months of 2024 due to difficult price negotiations with some key retail partners. The...

Trivago NV: 1 director

A director at Trivago NV sold 10,374 shares at 2.419USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri

Elmos Semiconductor SE : Solid Q1 2024 results, FY 2024 reiterated

>Strong Q1 2024 results - This morning, Elmos reported Q1 2024 results that beat expectations. Revenues were € 136.8m, above the consensus at € 135.4m. They were up 4.5% y-o-y but down 13% q-o-q. EBIT came in at € 33.8m, giving an EBIT margin of 24.7% above the consensus at € 31.7m and 23.4%. EPS was € 1.44 above consensus at € 1.27. Adjusted free cash flow stood at -€ 48.9m (vs € 35m in Q4 2023) impacted by year-end effects on working capital. Capex came in at € 20.3...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri

Elmos Semiconductor SE : Solid Q1 2024 results, FY 2024 reiterated

>Strong Q1 2024 results - This morning, Elmos reported Q1 2024 results that beat expectations. Revenues were € 136.8m, above the consensus at € 135.4m. They were up 4.5% y-o-y but down 13% q-o-q. EBIT came in at € 33.8m, giving an EBIT margin of 24.7% above the consensus at € 31.7m and 23.4%. EPS was € 1.44 above consensus at € 1.27. Adjusted free cash flow stood at -€ 48.9m (vs € 35m in Q4 2023) impacted by year-end effects on working capital. Capex came in at € 20.3...

Maria Vara ... (+2)
  • Maria Vara
  • Valliant Campagne

Medios: EBITDA hit by price regulations, reiterates outlook

Medios reported Q1 2024 results with revenue increasing 5.8% to EUR 456.2m led by 8.9% growth coming from the Pharmaceutical Supply (PS) segment, of which sales amounted to EUR 401m (EUR 368.1m), while the Patient-Specific Therapies (PTS) segment suffered from the 12.4% decline due to the divestmen

Maria Vara
  • Maria Vara

BICO: profitability impacted by mixed sales in Q1 2024; CMD in Septemb...

BICO has reported Q1 2024 net sales amounting to SEK 510.3m (+2% vs. css) implying 4.4% YoY growth and organic growth of 4.7% (-1.1%). The Biosciences segment outperformed with net sales showing 36.3% organic growth to SEK 310m (SEK 230m), while Bioprinting and Bioautomation fell short of expectati

Oliver Metzger
  • Oliver Metzger

Coloplast : Q2 review – Top and bottom line a slight miss, focus on LC...

>Q2 review – Miss on top and bottom line - Coloplast’s Q2 2024 revenues of DKK 6,586m (+8.7% y-o-y) were -1%/-2% vs ODDO BHF/consensus, driven by organic growth of 8% (7.3%/7.6% ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 300bp. Coloplast achieved an EBIT of DKK 1,772m (+7.3% y-o-y, margin 26.9%), which was -3%/-4% vs expectations. Profitability was supported by operating leverage and efficiency savings but impact...

 PRESS RELEASE

Syngenta extends leadership in fungicides with ADEPIDYN® technology

Syngenta Group / Key word(s): Miscellaneous Syngenta extends leadership in fungicides with ADEPIDYN® technology 07.05.2024 / 09:00 CET/CEST ADEPIDYN® technology on track to be first of Syngenta’s crop protection active ingredients to attain billion-dollar annual sales within eight years of commercialization   Following registration approval in Great Britain, farmers in more than 55 countries now have access to this powerful fungicide   Success reflects Syngenta’s innovation leadership in fungicides and the SDHI mode of action, and in bringing to market products with strong su...

 PRESS RELEASE

EQS-News: Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf ...

EQS-News: Biotest AG / Schlagwort(e): Quartalsergebnis Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf 215,2 Mio. Euro 07.05.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   PRESSEMITTEILUNG   Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf 215,2 Mio. Euro   Umsatz mit Produkten stieg um 17,7 % auf 138,0 Mio. Euro EBIT gesteigert auf 52,8 Mio. Euro Fibrinogenstudie erfolgreich abgeschlossen   Dreieich, 07. Mai 2024. Im ersten Quartal des Geschäftsjahres 2024 verzeichnete die Biotest Gr...

 PRESS RELEASE

EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in fi...

EQS-News: Biotest AG / Key word(s): Quarter Results Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024 07.05.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement.   PRESS RELEASE   Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024   Product sales increased by 17.7% to Euro 138.0 million EBIT increased to Euro 52.8 million Successful completion Fibrinogen study   Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 202...

Moody's assigns (P)A2 to Daikin's domestic shelf registration (Japanes...

1/4NEWSContact:東京 東京円城 ディーン セメトコ 真理子主任格付アナリスト/VPシニア・アナリスト 格付責任者/アソシエイト・マネージング・ディレクターコーポレート・ファイナンス・グループ コーポレート・ファイナンス・グループムーディーズ・ジャパン株式会社 ムーディーズ・ジャパン株式会社お客様専用電話番号:03-5408-4100報道関係者電話番号:03-5408-4110お客様専用電話番号:03-5408-4100報道関係者電話番号:03-5408-4110[MJKK]ダイキンの国内発行登録枠に(P)A2の予備格付を付与  2024年5月7日、東京、ムーディーズ・ジャパ...

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Sharad Kumar S.P
  • Wim Hoste
  • Wim Lewi
Paul de Froment ... (+3)
  • Paul de Froment
  • Sebastián Marroquin Mérida
  • Thomas Mordelle

HydrogenPro: Awaiting deliveries to Salzgitter and additional orders

Today, HydrogenPro reported Q1 2024 results which reflect slower activity than in previous quarters, with revenue of just NOK4m in Q1 2024 vs NOK83m in Q1 2023, NOK127m in Q4 2023 and cons. at NOK11m. As expected, revenues were impacted by the transition from the completion of ACES (US) and prepara

Bruno Duclos ... (+3)
  • Bruno Duclos
  • Eva Olejniczak
  • Stéphane Afonso
ABGSC Renewable Energy Research ... (+3)
  • ABGSC Renewable Energy Research
  • Haakon Amundsen
  • Stian Wibstad

Delivering in a difficult market

Q1 numbers basically spot-on estimates. Targets maintained and supported by solid visibility bridge. Stick to BUY, TP of NOK 11 (10).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch